BTIG on Humacyte (HUMA): stock appreciation limited NT, though updates expand Symvess utility
Tweet Send to a Friend
BTIG analyst Ryan Zimmerman reiterated a Buy rating and $6.00 price target on Humacyte (NASDAQ: HUMA)The analyst commented, "This morning ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
